Frequent loss of BRCA1 nuclear expression in young women with breast cancer: An immunohistochemical study from an area of low incidence but early onset

Applied Immunohistochemistry and Molecular Morphology

Volumn 10, Issue 4, 2002, Pages 310-315

  Lee, Wen Ying ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

BRCA1; c erbB 2; p53; Taiwan; Young women

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROTEIN BCL 2;

ADULT; AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; RISK FACTOR; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL NUCLEUS; FEMALE; GENE EXPRESSION; GENES, BRCA1; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036898601     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200212000-00004     Document Type: Article

References (37)

1. Bonnier P, Romain S, Charpin C, et al. Age as a prognostic factor in breast cancer: Relation to pathologic and biologic features. Int J Cancer 1995;62:138-44.
2. De La Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993;341:1039-43.
3. Chung M, Chang HR, Bland KI, et al. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996;77:97-103.
4. Schmidt RT, Tsangaris TN, Cheek, JH. Breast cancer in women under 35 years of age. Am J Surg 1991;162:197-201.
5. Nixon AJ, Neuberg D, Hayes DF, et al. Relation of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994;12:888-94.
6. Yildirim E, Dalgic T, Berberoglu U. Prognostic significance of young age in breast cancer. J Surg Oncol 2000;74:267-72.
7. Walker RA, Lees E, Webb M'B, et al. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 1996;74:1796-800.
8. Bertheau P, Steinberg SM, Merino MJ. C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: Immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 1998;29:323-9.
9. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: Are there age differentials? J Nat Cancer Inst Monogr 1994;16:35-42.
10. Pratap R, Shousha S. Breast carcinoma in women under the age of 50: Relation between p53 immunostaining, tumor grade, and axillary lymph node status. Breast Cancer Res Treat 1998;49:35-9.
11. Bogdani M, Teugels E, De Greve J, et al. Loss of nuclear BRCA1 localization in breast carcinoma is age dependent. Virchows Arch 2002;440:274-9.
12. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 1989;49:2087-90.
13. Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
14. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145:1191-8.
15. Wilson CA, Payton MN, Pekar SK, et al. BRCA1 protein products: Antibody specificity. Nat Genet 1996;13:264-5.
16. Scully R, Ganesan S, Brown M, et al. Location of BRCA1 in human breast and ovarian cancer cell. Science 1996;272:123-6.
17. Wilson CA, Ramos L, Villasenor MR, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999;21:236-40.
18. Chen Y, Chen CF, Riley DJ, et al. Aberrant subcellular localization of BRCA1 in breast cancer. Science 1995;270:789-91.
19. Lee WY, Jin YT, Chang TW, et al. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: A correlation with other biologic parameters. Histopathology 1999;34:106-12.
20. Jarvis EM, Kirk JA, Clarke CL. Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. Cancer Genet Cytogenet 1998;101:109-15.
21. Yoshikawa K, Honda K, Inamoto T, et al. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 1999;5:1249-61.
22. Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 1997;57:3347-50.
23. Robson M, Gilewski T, Haas B, et al. BRCA1-associated breast cancer in young women. J Clin Oncol 1998;16:1642-9.
24. Cortesi L, Turchetti D, Bertoni C, et al. Comparison between genotype and phenotype identifies a high risk population carrying BRCA1 mutations. Genes Chrom Cancer 2000;27:130-5.
25. Malone KE, Daling JR, Thompson JD, et al. BRCA1 mutations and breast cancer in the general population: Analyzes in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 1998;279:922-9.
26. Fitzgerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996;334:137-42.
27. Langston AA, Malone KE, Thompson JD, et al. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996;334:137-42.
28. Tang NL, Choy KW, Pang CP, et al. Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing. Clin Chim Acta 2001;313:179-85.
29. Cancer Registry Annual Report (1999), Republic of China. Taiwan. R.O.C.: Department of Health, the Executive Yuan, 1999.
30. Cheng SH, Tsou MH, Liu MC, et al. Unique features of breast cancer in Taiwan. Breast Cancer Res Treat 2000;63:213-23.
31. Lo YL, Yu JC, Huang CS, et al. Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset). Int J Cancer 1998;79:580-7.
32. Barbareschi M, Leonardi E, Mauri FA, et al. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 1992;98:408-18.
33. Doglioni C, Dei Tos AP, Laurino L, et al. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathologic correlates, with particular reference to oestrogen receptor status. Virchows Arch 1994;424:47-51.
34. Bottini A, Berruti A, Bersiga A, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000;6:2751-8.
35. Zhang H, Somasundaram K, Peng Y, et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 1998;16:1713-21.
36. Somasundaram K, Zhang H, Zeng YX, et al. Arrest of the cell cycle by the tumor-suppressor BRCAI requires the CDK-inhibitor p21WAF1/CiP1. Nature 1997;389:187-90.
37. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88:265-75.